Oncogenic KRAS leads to ROS production, NLRP3 activation and consecutive release of IL-1β in a myeloid leukemia mouse model, and KRAS-mutant human leukemia cells exhibit increased NLRP3 inflammasome activation [97]. Here, KRAS is linked to myeloid leukemia.